The United States Adopted Name (USAN) Council assigned the nonproprietary name of "dalzanemdor" to investigational SAGE-718, which is being studied for potential treatment of cognitive impairment associated with certain neurodegenerative diseases.

Dalzanemdor (SAGE-718) is an investigational N-methyl-D-aspartate (NMDA) receptor positive allosteric modulator (PAM) being studied in multiple ongoing placebo-controlled Phase 2 studies across multiple disease areas, including its cognitive impairment associated with Huntington's disease (HD), mild cognitive impairment (MCI) associated with Parkinson's disease and PD and MCI and mild dementia associated with Alzheimer's disease. The Company is also conducting a Phase 3 open-label safety study in HD cognitive impairment.

Nonproprietary names are commonly known as generic names and help facilitate the identification of medicines or active pharmaceutical ingredients. Dalzanemdor is also the International Nonproprietary Name (INN) for SAGE-718, which was coordinated through the World Health Organization for global usage.

About Sage Therapeutics

Sage Therapeutics is a biopharmaceutical company fearlessly leading the way to create a world with better brain health. Our mission is to pioneer solutions to deliver life-changing brain health medicines, so every person can thrive. For more information, please visit www.sagerx.com.

Investor Contact
Ashley Kaplowitz
786-252-1419
ashley.kaplowitz@sagerx.com

Media Contact
Matthew Henson
917-930-7147
matthew.henson@sagerx.com

Source: Sage Therapeutics, Inc.

Attachments

Disclaimer

Sage Therapeutics Inc. published this content on 05 December 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 December 2023 14:07:22 UTC.